Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

(2017) C. Batlevi et al.   HEMATOLOGICAL ONCOLOGY

PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION

(2017) L. Magnano et al.   HEMATOLOGICAL ONCOLOGY

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

(2016) Matthew J. Maurer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

(2016) V. Jurinovic et al.   BLOOD

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

(2016) Laurie H Sehn et al.   LANCET ONCOLOGY

Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma

(2015) VR Bhatt et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

(2013) D. Tan et al.   BLOOD

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

(2008) Robert Marcus et al.   JOURNAL OF CLINICAL ONCOLOGY